What the Case Involves
According to an adjudication sanction notice, the action centres on three products: NAN Excella Pro Stage 1, Lactogen Pro 1, and a Nestlé follow-up formula. FSSAI's scrutiny reportedly extended beyond the products themselves to promotional material available on e-commerce platforms, where certain claims appear to have triggered regulatory concern.
In the case of NAN Excella Pro Stage 1, FSSAI flagged promotional references to "5 HMOs" and "Whey Protein." After seeking an explanation from Nestlé India, the regulator concluded that the product violated Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020 — a provision that restricts promotional communication for infant foods when such messaging appears intended to boost saleability.
A similar issue arose with Lactogen Pro 1, where promotional material described its whey protein as "easy to digest." FSSAI again sought clarification from Nestlé India and found this product, too, in contravention of the same Regulation 4(2).
The third case is arguably the more serious of the three, relating not to marketing language but to actual nutritional composition. Laboratory testing on a sample of Nestlé's follow-up formula found that it did not meet the prescribed standard for biotin content — a finding that held up even after the sample was sent for re-analysis to a Referral Laboratory, which also confirmed non-compliance.
Why This Matters
Infant nutrition sits in a uniquely sensitive regulatory category — unlike most packaged foods, these products are consumed by infants who have no dietary alternatives and are entirely dependent on the nutritional accuracy of what's in the tin. This is precisely why India's 2020 regulations place strict limits on promotional language: claims that make a formula sound more advanced, more digestible, or more "premium" than warranted could influence purchasing decisions in ways that go beyond typical consumer marketing concerns.
Biotin (vitamin B7) plays a role in several essential bodily functions, and prescribed nutritional standards for infant formula exist precisely to ensure products meet the specific developmental needs of infants — who cannot compensate for nutritional shortfalls the way an adult might through diet variety. A composition failure, even in a single nutrient, is treated with particular seriousness in this category.
The Bigger Picture
This case puts a spotlight on the layered nature of infant food regulation in India — covering not just what's inside the product, but also how it's marketed. The fact that two of the three violations relate to promotional language, rather than composition, suggests regulators are paying close attention to how infant formula claims are framed for consumers, particularly on e-commerce platforms where such claims are highly visible and easily compared across brands.
The composition-related finding, meanwhile, reinforces why regulatory bodies conduct laboratory verification rather than relying solely on manufacturer disclosures — and why a re-analysis step exists to confirm results before formal action is taken.
What Comes Next
Further developments are awaited on how Nestlé India responds to the adjudication proceedings, whether promotional material for the flagged products will be revised, and what corrective steps — if any — are taken regarding the biotin-content finding. The case may also prompt closer scrutiny of promotional claims across other infant nutrition brands sold on e-commerce platforms in India.
